Effectiveness and Safety of Drug-Eluting Stents in Ontario
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The placement of drug-eluting stents decreases the frequency of repeat revascularization procedures in patients undergoing percutaneous coronary intervention (PCI) in randomized clinical trials. However, there is uncertainty about the effectiveness of drug-eluting stents, and increasing concern about their safety, in routine clinical practice. METHODS: From the Cardiac Care Network of Ontario's population-based clinical registry of all patients undergoing PCI in Ontario, Canada, we identified a well-balanced cohort of 3751 pairs of patients, matched on the basis of propensity score, who received either bare-metal stents alone or drug-eluting stents alone during an index PCI procedure between December 1, 2003, and March 31, 2005. The primary outcomes of the study were the rates of target-vessel revascularization, myocardial infarction, and death. RESULTS: The 2-year rate of target-vessel revascularization was significantly lower among patients who received drug-eluting stents than among those who received bare-metal stents (7.4% vs. 10.7%, P<0.001). Drug-eluting stents were associated with significant reductions in the rate of target-vessel revascularization among patients with two or three risk factors for restenosis (i.e., presence of diabetes, small vessels [<3 mm in diameter], and long lesions [> or =20 mm]) but not among lower-risk patients. The 3-year mortality rate was significantly higher in the bare-metal-stent group than in the drug-eluting-stent group (7.8% vs. 5.5%, P<0.001), whereas the 2-year rate of myocardial infarction was similar in the two groups (5.2% and 5.7%, respectively; P=0.95). CONCLUSIONS: Drug-eluting stents are effective in reducing the need for target-vessel revascularization in patients at highest risk for restenosis, without a significantly increased rate of death or myocardial infarction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 15% of patients with T2DM will require target vessel revascularization within 2 years after bare metal stenting,290”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [290]
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., & Kaiser, C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.026 · Cited by 1,303
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Grines, C. L., Bonow, R. O., Casey, D. E., Gardner, T. J., Lockhart, P. B., Moliterno, D. J., O’Gara, P., & Whitlow, P. (2007) · Circulation · doi:10.1161/circulationaha.106.180944 · Cited by 1,140
Austin, P. C., Grootendorst, P., & Anderson, G. M. (2007) · Statistics in Medicine · doi:10.1002/sim.2580 · Cited by 1,137
Self-citation
Research works printed but not linked: 1
- Wilkins R, 1993, Health Rep, 5, 157
Cited by
Items 201–300 of 383
Thim, T., Mæng, M., Kaltoft, A., Jensen, L. O., Tilsted, H. H., Hansen, P. R., Kelbæk, H., Thayssen, P., Ravkilde, J., Madsen, M., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02692.x · Cited by 10
Differences Between Early, Intermediate, and Late Angioplasty After Coronary Artery Bypass Grafting
Tan, E. S., Jessurun, G. A. J., Deurholt, W., van der Vleuten, P., van den Heuvel, A. F. M., Ebels, T., Zijlstra, F., & Tio, R. A. (2008) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e3181894550 · Cited by 10
Onuma, Y., Kukreja, N., Ramcharitar, S., Hochadel, M., Gitt, A., & Serruys, P. W. J. C. (2009) · EuroIntervention · doi:10.4244/eijv4i5a98 · Cited by 10
Long-term outcomes of patients receiving drug-eluting stents
Philpott, A. C., Southern, D. A., Clement, F. M., Galbraith, P. D., Traboulsi, M., Knudtson, M. L., Ghali, W. A., & for the APPROACH Investigators (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080050 · Cited by 10
Schwalm, J.-D. R., Ahmad, M., Velianou, J. L., Pericak, D., & Natarajan, M. K. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70005-2 · Cited by 9
Canouï‐Poitrine, F., Jeanblanc, G., Alberti, C., Armoogum, P., Cebrián, A., Carrié, D., Henry, P., Teíger, E., Slama, M., Spaulding, C. M., et al. (2009) · Applied Health Economics and Health Policy · doi:10.1007/bf03256139 · Cited by 9
Firth, B. G., Cooper, L. M., & Fearn, S. (2008) · Health Affairs · doi:10.1377/hlthaff.27.6.1577 · Cited by 9
Stolker, J. M., Cohen, D. J., Kennedy, K. F., Pencina, M. J., Arnold, S. V., Kleiman, N. S., & Spertus, J. A. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.12.014 · Cited by 10
Manari, A., Ortolani, P., Guastaroba, P., Marzaroli, P., Menozzi, M., Magnavacchi, P., Varani, E., Vignali, L., Campo, G. C., & Marzocchi, A. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833e58e4 · Cited by 9
Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007
Daemen, J., Simoons, M. L., Wijns, W. C., Bagust, A., Bos, G. W., Bowen, J. M., D, E. B. M., Camenzind, E., Chevaliers, B., Mario, C. D., et al. (2009) · EuroIntervention · doi:10.4244/eijv4i4a75 · Cited by 9
“Drug-eluting stents (DES) were introduced into clinical practice in 2002 in order to reduce restenosis that occurred in 15–25% of patients receiving bare-metal stents (BMS).1– 3 Subsequent trials with different types of DES confirmed their efficacy in this regard.4 However, late stent thrombosis was reported as early…”
InfluentialSelf-citationWang, X., Xu, K., Li, Y., Jing, Q., Liu, H., Zhao, X., Wang, G., Wang, B., Ma, Y., Chen, S., et al. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.152460 · Cited by 8
“Because restenosis or repeat revascularization of the LMCA may result in death or MI,[25] the higher risk of restenosis after BMS implantation may counterbalance the potential risk of ST‑mortality after DES implantation.”
BackgroundInfluentialShugman, I., Idris, H., Kadappu, K. K., Nguyen, P., Taylor, D., Rajaratnam, R., Leung, D. Y., Hopkins, A. P., Lo, S. T., Juergens, C., et al. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2012.12.011 · Cited by 8
“16 [12–24], p< 0.”
BackgroundMethodInfluentialBare‐metal stent versus drug‐eluting stent in large coronary arteries
Geng, D.-F., Zhe, M., Yan, H., Nie, R., Deng, J., & Wang, J. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24599 · Cited by 8
“Subanalysis for a propensity-score– matched study [20] indicated that the rates of TVR were comparable between the DES group and the BMS group in patients with large vessel diameters and short lesions, while the risk of TVR was in favor of DES in Fig.”
ResultRevascularization vs. Medical Therapy in Stable Ischemic Heart Disease
Weiss, S. A., & Weintraub, W. S. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.005 · Cited by 8
“to BMS, the widespread use of BMS in COURAGE is of some concern as restenosis may have accounted for a significant portion of repeat revascularizations in the PCI group[38-41].”
MethodAre drug-eluting stents safe in the long term?
Généreux, P., & Mehran, R. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081907 · Cited by 8
“In contrast, greater reductions in all-cause mortality, by up to 20%, with drug-eluting stents than with bare-metal stents have been shown in observational studies, such as the one by Tu and colleagues.(7) In a recent, large observational study, Mauri and colleagues(8) conducted an analysis of matched propensity score…”
BackgroundBowen, J. M., Patterson, L. L., O’Reilly, D. J., Hopkins, R. B., Blackhouse, G., Burke, N., Xie, F., Tarride, J., & Goeree, R. A. (2009) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2009.01.023 · Cited by 8
Self-citationThe Question of Drug-Eluting Stent Safety: Then and Now
Spaulding, C. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.004 · Cited by 8
Collet, J., & Montalescot, G. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.202 · Cited by 8
“This issue was further examined in a number of observational studies using registry data from Denmark [31], Sweden [32], and Canada [33].”
BackgroundFederspiel, J. J., Stearns, S. C., Sheridan, B. C., Kuritzky, J. J., D'Arcy, L. P., Crespin, D., Carey, T. S., & Rossi, J. S. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.05.016 · Cited by 10
Džavík, V., Buller, C. E. H., Devlin, G. P., Carere, R. G., Mancini, G. B. J., Cantor, W. J., Buszman, P. E., Rankin, J. M., Vozzi, C. R., ROSS, J. R., et al. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21930 · Cited by 8
“Thus, even though there are concerns regarding a possible increased risk of late stent thrombosis after DES implantation [18,19], more recent data indicate that this incremental risk of late stent thrombosis does not translate into a higher mortality risk [20,21].”
BackgroundStress testing after percutaneous coronary interventions: a population-based study
Luca, S. R., Koh, M., Qiu, F., Alter, D. A., Bagai, A., Bhatia, R. S., Czarnecki, A., Goodman, S. G., Lau, C., Wijeysundera, H. C., et al. (2017) · CMAJ Open · doi:10.9778/cmajo.20160159 · Cited by 8
Self-citationDrug-Eluting Stents Versus Bare-Metal Stents in Patients With Decreased GFR: A Meta-analysis
Wang, Z. J., Harjai, K. J., Shenoy, C., Gao, F., Shi, D. M., Liu, Y. Y., Zhao, Y. X., & Zhou, Y. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.04.014 · Cited by 7
Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients
Chiu, M., Ko, D. T., Austin, P. C., Cohen, E. A., Velianou, J. L., Goeree, R. A., Blackhouse, G., & Tu, J. V. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.826057 · Cited by 7
Self-citationBeijk, M. A. M., Koch, K. T., Tijssen, J. G. P., Henriques, J. P. S., Baan, J., Vis, M. M., Meesterman, M. G., Piek, J. J., & de Winter, R. J. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e328340b824 · Cited by 7
Park, H., Ahn, J., Kang, D., Kim, S., Ko, E., Kim, T. O., Lee, P. H., Lee, S., Park, S., Park, D., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.05.009 · Cited by 7
Feng, J., Wang, Y., Liu, T., Huo, J., Zhuo, Q., & Gong, Z. (2022) · Nutrients · doi:10.3390/nu14214539 · Cited by 9
“PSM is a statistical method that can effectively reduce some biases and confounding variables, thus allowing for a more reasonable comparison between groups [32,33].”
MethodApplegate, R. J., Hermiller, J. B., Sanz, M. L., Doostzadeh, J., Pierson, W., Su, X., Lansky, A. J., Sudhir, K., & Stone, G. W. (2010) · EuroIntervention · doi:10.4244/eij30v6i4a75 · Cited by 7
Gardner, C., Rankin, J. M., Geelhoed, E. A., Nguyen, M., Newman, M. A. J., Cutlip, D. E., Knuiman, M. W., Briffa, T. G., Hobbs, M., & Sanfilippo, F. M. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006337 · Cited by 7
“illness (site of revascularisation, number of vessels treated) and (15) use of cardioprotective drugs.”
BackgroundCantor, W. J., Ko, D. T., Natarajan, M. K., Džavík, V., Wijeysundera, H. C., Wang, J. T., Kingsbury, K., Velianou, J. L., Cohen, E. A., May, M. R. L., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002097 · Cited by 7
“This clinical database has been previously used as a valuable resource in clinical research.(6,7) In 2010, a registry was established within CCN to capture clinical characteristics, procedural details, and treatment times for all STEMI patients in Ontario undergoing urgent cardiac catheterization.”
MethodSelf-citationPercutaneous coronary intervention as an alternative to bypass surgery for unprotected LMCA stenosis
Park, S., & Kim, Y. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.8.1107 · Cited by 7
Lo, N., Kotsia, A. P., Christopoulos, G., Roesle, M. K., Rangan, B. V., Kim, B. J., Webb, A., Banerjee, S., & Brilakis, E. S. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.04.027 · Cited by 7
Roifman, I., Han, L., Koh, M., Wijeysundera, H. C., Austin, P. C., Douglas, P. S., & Ko, D. T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017330 · Cited by 5
Self-citationOptimale Thrombozytenaggregationshemmung nach koronarer Stentimplantation: Aktueller Stand
Silber, S., Hoffmeister, H. M., & Bode, C. (2008) · Herz · doi:10.1007/s00059-008-3138-9 · Cited by 8
Rossini, R., Musumeci, G., Aprile, A., & Valsecchi, O. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.1 · Cited by 6
Harjai, K. J., Sattur, S., Orshaw, P., & Boura, J. (2011) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2011.00677.x · Cited by 6
Review: The safety of drug-eluting stents
Saia, F., Marzocchi, A., & Branzi, A. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707088158 · Cited by 6
Gordon, P. C., Cohen, D. J., Kleiman, N. S., Montgomery, J. A., Semder, C. A., Kennedy, K. F., Keyes, M. J., Piana, R. N., & on behalf of the EVENT Investigators (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24451 · Cited by 6
Ahmed, W., Shah, M. A., Thaver, A. M., & Mirza, J. (2011) · PubMed · Cited by 6
da Costa, R. A., Sousa, A. G. M. R., Moreira, A. C., Costa, J. R., Maldonado, G. A., Cano, M. N., Tanajura, L. F., Feres, F., Mattos, L. A., Staico, R., et al. (2008) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972008000200007 · Cited by 6
Anderson, H. V. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.053 · Cited by 6
Choosing Methods to Minimize Confounding in Observational Studies
Yeh, R. W., & Mauri, L. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.963538 · Cited by 6
Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients
Cook, S., & Windecker, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.002 · Cited by 5
Kollum, M., Heitzer, T. A., Schmoor, C., Brunner, M., Witzenbichler, B., Wiemer, M., Hoffmann, R., Gutleben, K. J., Schultheiss, H. P., Horstkotte, D., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.04.095 · Cited by 5
“Drug eluding stents (DES) decrease late luminal loss, decrease the incidence of angiographic restenosis and the subsequent need of revascularization procedures [1–5] mainly by inhibiting neointimal proliferation.”
BackgroundRevascularisation of coronary artery disease in patients with diabetes mellitus
Cook, S., & Windecker, S. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12707 · Cited by 5
Beyond restenosis: Patients' preference for drug eluting or bare metal stents
Qintar, M., Chhatriwalla, A. K., Arnold, S. V., Tang, F., Buchanan, D. M., Shafiq, A., Pokharel, Y., deBronkart, D., Ashraf, J. M., & Spertus, J. A. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26946 · Cited by 7
“Importantly, the benefits of DES in preventing repeat revascularization procedures are highly dependent on an individual patient’s risk for restenosis, with the number needed to treat to avoid one target vessel revascularization (TVR) ranging from 6 to 130, depending on individual patient characteristics [9,10].”
BackgroundBaumbach, A., Heg, D., Räber, L., Ostoijc, M., Brugaletta, S., Strange, J., Johnson, T., Jüni, P., Engstrøm, T., Serruys, P. W. J. C., et al. (2017) · EuroIntervention · doi:10.4244/eij-d-15-00408 · Cited by 5
Jeschke, E., Searle, J., Günster, C., Baberg, H. T., Dirschedl, P., Levenson, B., Malzahn, J., Mansky, T., & Möckel, M. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017460 · Cited by 5
Liu, Z., Li, J., Zhang, Y., Yu, B., Ma, Y.-T., Ma, G., Wang, J., Liu, B., Su, X., Li, B., et al. (2022) · Cardiology Plus · doi:10.1097/cp9.0000000000000021 · Cited by 5
All-cause mortality after drug-eluting stent implantation in African–Americans
Poludasu, S., Çavuşoğlu, E., Khan, W., & Marmur, J. D. (2008) · Coronary Artery Disease · doi:10.1097/mca.0b013e3283109033 · Cited by 5
Chen, Y., Yip, H., Chen, C., Yang, C., Fang, C.-Y., Hsieh, Y., Hang, C., & Wu, C. (2009) · Cited by 5
Wang, X., Rokoss, M. J., Dyub, A. M., Gafni, A., & Lamy, A. L. (2008) · Journal of Medical Economics · doi:10.3111/13696990801954756 · Cited by 5
The ever increasing role of percutaneous interventions in coronary revascularisation.
Spanos, V., & TOUTOUZAS, P. K. (2010) · PubMed · Cited by 5
Effect of Stent Thrombosis on the Risk-Benefit Balance of Drug-Eluting Stents and Bare Metal Stents
Rios, X. F., Abugattás-Torres, J. P., Campo-Pérez, R., Piñón-Esteban, P., Aldama‐López, G., Salgado‐Fernández, J., Calviño‐Santos, R., Vázquez‐Rodríguez, J. M., Vázquez‐González, N., & Castro‐Beiras, A. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70114-6 · Cited by 5
Prior Authorization and Clopidogrel Use - The Truth Lies in the Details
Jackson, M. A., Fairman, K. A., & Curtiss, F. R. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.1.71 · Cited by 5
“1 This assessment discounts the results reported by Tu et al. (2007), who found a significantly lower 2-year rate of target-vessel revascularization for patients receiving drug-eluting stents as compared with a propensity score-matched cohort of patients receiving bare-metal stents in Ontario,…”
How Should We Treat Multi-Vessel Disease in STEMI Patients?
Hsieh, V., & Mehta, S. R. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0213-6 · Cited by 4
Cobalt Chromium Coronary Stents and Drug-Eluting Stents in Real Practice
Youssef, A. A., Hussein, H., Hsueh, S., Chen, C.-J., Yang, C., Hang, C., Hsieh, Y., Fang, C.-Y., Yip, H., & Wu, C. (2010) · International Heart Journal · doi:10.1536/ihj.51.231 · Cited by 4
Petrou, P., & Dias, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.134 · Cited by 4
Evolution und Zukunftsperspektiven der perkutanen Koronarintervention (PCI)
Meier, B. (2010) · BORIS (University Library Bern) · Cited by 4
Chhatriwalla, A. K., Venkitachalam, L., Kennedy, K. F., Stolker, J. M., Jones, P. G., Cohen, D. J., & Spertus, J. A. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.021 · Cited by 4
Drug-eluting stents in patients at high risk of restenosis: Assessment for France
Schapiro-Dufour, E., Cucherat, M., Velzenberger, E., Galmiche, H., Denis, C., & Machecourt, J. (2011) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462311000134 · Cited by 4
“There was no significant difference in death and myocardial infarction (MI) rates but, according to several prospective observational comparative studies, the rates of death or MI were reported lower with DES (1;2;4;6;9;10;14;19;21;25).”
ResultPercutaneous Coronary Intervention in Perspective
Kandzari, D. E., Farb, A. A., & Boam, A. B. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.871996 · Cited by 4
Validation of a risk score for target vessel revascularization after coronary stent implantation.
de Quadros, A. S., Diemer, F., Welter, D., Modkovski, T. B., Sarmento‐Leite, R., & Gottschall, C. A. M. (2009) · PubMed · Cited by 4
Alsayed, K. (2020) · International Journal of Medical Arts · doi:10.21608/ijma.2020.35338.1145 · Cited by 4
“Diabetic patients, longer lesions [>15 mm], small diameter vessels [<3 mm] must be treated with DES, unless DAPT is contraindicated[8-9].”
Should We Routinely Use Drug-Eluting Stents for Acute Myocardial Infarction?
Grines, C. L., Goldstein, J. A., & Safian, R. D. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.02.006 · Cited by 4
Lasave, L. I., Costa, J. R., Abizaid, A., Feres, F., Sanchez, A., da Costa, R. A., Staico, R., Siqueira, D. A., Mattos, L. A., Tanajura, L. F., et al. (2008) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972008000100007 · Cited by 3
Os stents farmacológicos são seguros e eficazes em longo prazo?
Sastry, S., & Morice, M. (2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010001500016 · Cited by 3
Shuvy, M., Guo, H., Wijeysundera, H. C., Feindel, C. M., Cohen, E. A., Austin, P. C., Kingsbury, K., Natarajan, M. K., Tu, J. V., & Ko, D. T. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.020 · Cited by 3
Self-citationKereiakes, D. J. (2009) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0005-9 · Cited by 3
A completely fractured zotarolimus‐eluting stent in an aortocoronary saphenous vein bypass graft
Venero, C. V., Aligeti, V. R., & Wortham, D. C. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24312 · Cited by 3
Percutaneous coronary intervention for unprotected left main coronary artery stenosis
Park, S. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i4.78 · Cited by 3
Yock, C. A., Jm, I., rd, K. S., & Hlatky, M. A. (2010) · PubMed · Cited by 3
Kawamura, Y., Tamura, N., Goto, S., & Goto, S. (2021) · Journal of Interventional Cardiology · doi:10.1155/2021/8880988 · Cited by 4
“Drug-eluting stents were proven to be effective in reducing the need for target vessel revascularization in patients at high risk for restenosis without a significant increase in the risk of myocardial infarction or death [12].”
BackgroundOff-label use of stents: bare-metal versus drug-eluting stents
Girod, J. P., Mulukutla, S. R., & Marroquin, O. C. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.8.1095 · Cited by 3
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?
Colombo, A., & Gerber, R. T. (2008) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.108.810853 · Cited by 3
Windecker, S., & Räber, L. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.11.008 · Cited by 3
Tanajura, L. F., Feres, F., Abizaid, A., Mattos, L. A., Siqueira, D., Centemero, M. P., Chaves, A. J., Abizaid, A. S., Sousa, A. G. M. R., & Sousa, J. E. (2008) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972008000100008 · Cited by 2
Advances in Coronary Revascularization
Baron, S. J., Mick, S., Shekar, P., & Mauri, L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00011-4 · Cited by 2
Uso de stents farmacológicos na "vida real": a importância dos registros
Ribeiro, E. E., & Ribeiro, H. B. (2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010001100019 · Cited by 2
Rios, X. F., Abugattás-Torres, J. P., Campo-Pérez, R., Piñón-Esteban, P., Aldama‐López, G., Salgado‐Fernández, J., Calviño‐Santos, R., Vázquez‐Rodríguez, J. M., Vázquez‐González, N., & Castro‐Beiras, A. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70114-7 · Cited by 2
Time dependent effect on mortality of drug-eluting stents versus bare metal stents
Mølstad, P. (2012) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2012.681308 · Cited by 2
Evolving challenges in medical device evaluation
Holmes, D. R., Firth, B. G., Hodgson, P. K., Rihal, C. S., Wood, D. L., & Cohen, D. J. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21541 · Cited by 2
Stenting in Acute STEMI Intervention
Magdy, A., Selim, H., & Youssef, M. (2012) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2012.06.007 · Cited by 2
Choice of drug-eluting stent—evidence-based or empirical
Kaul, U., & Mansoor, A. (2012) · Journal of Indian College of Cardiology · doi:10.1016/s1561-8811(12)80005-8 · Cited by 2
Why don’t we return to bare metal stents?
Hess, O. M. (2008) · EuroIntervention · doi:10.4244/eijv4i1a6 · Cited by 2
Mæng, M., Jensen, L. O., Kaltoft, A., Tilsted, H., Christiansen, E. H., Thayssen, P., Madsen, M., Sørensen, H. T., Lassen, J. F., & Thuesen, L. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-84 · Cited by 2
“Background Introduction of first-generation drug-eluting stents (DESs) more than halved the need for target lesion revascularization (TLR) after coronary stent implantation [1-6].”
BackgroundGarg, S., & Serruys, P. W. J. C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.99 · Cited by 2
“These favorable results are not confined solely to the select patients from randomized controlled trials (RCTs) but have been consistently reproduced in registries, including those with patients receiving DESs for off- label indications”
BackgroundRobinson, J. W. (2012) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.12.4 · Cited by 2
Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry
Feldman, D. A., Shroff, A. R., Bao, H., Curtis, J. P., Minges, K. E., & Ardati, A. K. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28698 · Cited by 2
The Year in Interventional Cardiology
Dixon, S. R., Grines, C. L., & O’Neill, W. W. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.021 · Cited by 2
Ananthakrishna, R., Loh, J. P.-Y., Shen, L., Low, A. F.-H., Lee, C., & Tan, H. C. (2018) · AsiaIntervention · doi:10.4244/aij-d-17-00039 · Cited by 2
Mølstad, P., Nordrehaug, J. E., Steigen, T. K., Giil, L. M., Wilsgaard, T., Wiseth, R., & Bønaa, K. H. (2020) · Cardiology · doi:10.1159/000506042 · Cited by 2
“Thus, the duration of the clinical effect of DES concerning TLR in this study seems to be in concert with previous reports [6, 24].”
BackgroundResultSwitzerland Reports Žcourant normal in interventional cardiology, 30 years after inventing it
Meier, B. (2010) · Kardiovask Med · doi:10.4414/cvm.2010.01472 · Cited by 2
Trenk, D., & Neumann, F. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0434-x · Cited by 2
“Thus, there is currently no evidence that the implantation of DES exposes the patient to an increased risk of death or myocardial infarction if compared with bare-metal stent implantation [33].”
Juliard, J. (2009) · Sang thrombose vaisseaux · doi:10.1684/stv.2009.0416 · Cited by 1
Piccolo, R., & Windecker, S. (2017) · CRC Press eBooks · doi:10.1201/9781315113869-32 · Cited by 1
Stent choice and the hidden consequences of cost savings
Cavender, M. A., & Ellis, S. G. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.124 · Cited by 1
Author's response: the design of observational studies—defining baseline time
Austin, P. C., & Platt, R. W. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.07.018 · Cited by 1
“For instance, when comparing the safety and efficacy of drug-eluting stents with those of bare metal stents in percutaneous coronary interventions (PCI), baseline time is the time immediately before the PCI procedure [4].”
BackgroundSelf-citationPerioperative Antiplatelet Management in Patients with Coronary Artery Stenting
Tandar, A., Velagapudi, K., Wilson, B. D., & Boden, W. E. (2012) · Hospital Practice · doi:10.3810/hp.2012.04.977 · Cited by 1
Mboup, M. C., Moquet, B., Zabalawi, A., & Delaunay, R. (2012) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2012.01.002 · Cited by 1
Evidence-based healthcare and the need of conditional decision
Park, S., & Lee, S. M. (2011) · Journal of Korean Medical Association · doi:10.5124/jkma.2011.54.12.1319 · Cited by 1
Metadata
- Authors
- Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., & Goeree, R.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Institute for Clinical Evaluative Sciences (CA)
- Trillium Health Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-04
- Volume
- 357
- Issue
- 14
- Pages
- 1393-1402
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2082511254
- Cited by
- 383
- References
- 35
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 5 · 2017: 13 · 2016: 15 · 2015: 28 · 2014: 15 · 2013: 15 · 2012: 34
- FWCI
- 67.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- drug-eluting stents, bare-metal stents, percutaneous coronary intervention, target vessel revascularization, restenosis, myocardial infarction, mortality, diabetes mellitus, long coronary lesions, propensity score matching, clinical registries, Ontario
- MeSH terms
- Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Ontario, Prosthesis Design, Registries, Risk Factors, Stents, Angioplasty, Balloon, Coronary, Drug Delivery Systems, Myocardial Ischemia, Disease-Free Survival, Coronary Restenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.